A novel human epidermal growth factor receptor-3 targeting antibody-drug conjugate for treatment of cancer
An Italian SME specialized in drug discovery has developed and patented a novel human epidermal growth factor receptor-3 (HER-3) targeting antibody-drug conjugate (ADC) for treating cancer. This molecule has shown potent therapeutic efficacy combined with a good safety profile. The company is looking for pharmaceutical companies or investors for financial or license agreement to further develop the product in clinical trials. A research cooperation agreement is also foreseen.
The company is looking for pharmaceutical companies or investors (VC, Banks, Private Investors) interested in financial or license agreement to further develop the product in clinical trials. A research cooperation agreement with a technological partner (pharmaceutical company, R&D Institutions) with expertise and interest in therapeutic antibody or/and ADC technology could also be considered. During the cooperation, the partner is expected to set-up and upscaling manufacturing process of the anti-HER3 antibody in accordance with good manufacturing practice (GMP) and regulatory, among others.
HER-3 plays an important role in the growth, progression and development of drug resistance in several cancers. HER-3 is kinase impaired, therefore its inhibition can only be obtained through use of a neutralizing antibody. Several “naked” monoclonal antibodies targeting HER-3 have been developed, however the results from the clinic have revealed a modest effect in several types of cancer. It is conceivable that a substantial improvement over this immunotherapeutic approach could rely on an anti-HER3 based ADC. An Italian SME located in Central Italy, specialized in drug discovery, has developed and patented an anti-HER3 monoclonal antibody which has been used as a building block of a HER-3 targeting ADC. This molecule has shown potent therapeutic activity against several types of cancer and has good safety profile combined with a favorable pharmacokinetics. The product is in pre-clinical stage of development. In order to submit the application for phase 1 trial, the following steps have to be performed: (i) generation of a stable antibody producing cell line and a master cell bank (ii) production of drug substance batch and performing a toxicology study (iii) production of clinical drug substance batches. Pharmaceutical companies or investors for financial or license agreement to further develop the product in clinical trials are sought. The company is also interested in a research cooperation agreement.
Advantages and innovations
The company has generated a novel ADC by coupling its proprietary anti-HER3 humanized monoclonal antibody with a potent cytotoxic antitumor drug through a linker. Compared with the naked antibody, the resulting ADC displays a potent, long lasting remission of several types of cancer. Also, the product shows a good safety profile in animals combined with favorable pharmacokinetics. HER-3 is overexpressed in more than 50% of human cancers. Therefore, possible indications in oncology are manifold and include, among others: lung cancer, colorectal cancer, ovarian cancer, prostate cancer, breast cancer resistant to anti-HER2 drugs and melanoma. ADC is one of the fastest growing segments of the global pharmaceutical industry, with six ADCs approved and more than 80 in clinical development.
Under development/lab tested
Intellectual Property Rights (IPR)
Register your interest
How it works
- Tell us about yourself
- We’ll discuss with you
- We put the right partners in touch
EEN help you find the right partner, rather than you going it alone.
Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.
These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.
Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.
First we need to check you’re human.
Thank you for verifying your email. We have sent you a confirmation email containing a 6 digit verification code to unlock the form below